Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells.

Gaedicke S, Braun F, Prasad S, Machein M, Firat E, Hettich M, Gudihal R, Zhu X, Klingner K, Schüler J, Herold-Mende CC, Grosu AL, Behe M, Weber W, Mäcke H, Niedermann G.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E692-701. doi: 10.1073/pnas.1314189111. Epub 2014 Jan 27.


Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.

Lang J, Lan X, Liu Y, Jin X, Wu T, Sun X, Wen Q, An R.

Nucl Med Biol. 2015 May;42(5):505-12. doi: 10.1016/j.nucmedbio.2015.01.003. Epub 2015 Jan 9.


Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.

Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schüler J, Wider D, Wäsch RM, Herold-Mende C, Elsässer-Beile U, Niedermann G.

Cancer Res. 2015 Jun 1;75(11):2166-76. doi: 10.1158/0008-5472.CAN-14-2415. Epub 2015 Apr 3.


[The CD133 polyclonal antibody generation and cancer stem cells identification].

Tian JL, Cai PL, Xia XQ, Li FH, Wang DH, Chen MN.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2011 May;42(3):422-6. Chinese.


The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.

Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP.

Cancer Res. 2010 Jan 15;70(2):719-29. doi: 10.1158/0008-5472.CAN-09-1820. Epub 2010 Jan 12.


Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.

Ji J, Judkowski VA, Liu G, Wang H, Bunying A, Li Z, Xu M, Bender J, Pinilla C, Yu JS.

Stem Cells Transl Med. 2014 Mar;3(3):356-64. doi: 10.5966/sctm.2013-0135. Epub 2013 Dec 27.


CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.

Barrantes-Freer A, Renovanz M, Eich M, Braukmann A, Sprang B, Spirin P, Pardo LA, Giese A, Kim EL.

PLoS One. 2015 Jun 18;10(6):e0130519. doi: 10.1371/journal.pone.0130519. eCollection 2015.


Selective lentiviral gene delivery to CD133-expressing human glioblastoma stem cells.

Bayin NS, Modrek AS, Dietrich A, Lebowitz J, Abel T, Song HR, Schober M, Zagzag D, Buchholz CJ, Chao MV, Placantonakis DG.

PLoS One. 2014 Dec 26;9(12):e116114. doi: 10.1371/journal.pone.0116114. eCollection 2014.


Development of clinically relevant orthotopic xenograft mouse model of metastatic lung cancer and glioblastoma through surgical tumor tissues injection with trocar.

Fei XF, Zhang QB, Dong J, Diao Y, Wang ZM, Li RJ, Wu ZC, Wang AD, Lan Q, Zhang SM, Huang Q.

J Exp Clin Cancer Res. 2010 Jun 29;29:84. doi: 10.1186/1756-9966-29-84.


Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties.

Bostad M, Berg K, Høgset A, Skarpen E, Stenmark H, Selbo PK.

J Control Release. 2013 Jun 28;168(3):317-26. doi: 10.1016/j.jconrel.2013.03.023. Epub 2013 Apr 6.


Non-invasive in vivo imaging of tumor-associated CD133/prominin.

Tsurumi C, Esser N, Firat E, Gaedicke S, Follo M, Behe M, Elsässer-Beile U, Grosu AL, Graeser R, Niedermann G.

PLoS One. 2010 Dec 20;5(12):e15605. doi: 10.1371/journal.pone.0015605.


Insight into the complex regulation of CD133 in glioma.

Campos B, Herold-Mende CC.

Int J Cancer. 2011 Feb 1;128(3):501-10. doi: 10.1002/ijc.25687. Review.


RNA aptamers targeting cancer stem cell marker CD133.

Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, Lim LY, Kong L, Li L, Duan W.

Cancer Lett. 2013 Mar 1;330(1):84-95. doi: 10.1016/j.canlet.2012.11.032. Epub 2012 Nov 27.


Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody.

Wang CH, Chiou SH, Chou CP, Chen YC, Huang YJ, Peng CA.

Nanomedicine. 2011 Feb;7(1):69-79. doi: 10.1016/j.nano.2010.06.010. Epub 2010 Jul 8.


Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.

Xiang T, Long H, He L, Han X, Lin K, Liang Z, Zhuo W, Xie R, Zhu B.

Oncogene. 2015 Jan 8;34(2):165-76. doi: 10.1038/onc.2013.537. Epub 2013 Dec 23.


CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.

Lehnus KS, Donovan LK, Huang X, Zhao N, Warr TJ, Pilkington GJ, An Q.

Int J Oncol. 2013 Mar;42(3):1011-7. doi: 10.3892/ijo.2013.1787. Epub 2013 Jan 22.


Targeting cancer stem cells through L1CAM suppresses glioma growth.

Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN.

Cancer Res. 2008 Aug 1;68(15):6043-8. doi: 10.1158/0008-5472.CAN-08-1079.


CD133 is essential for glioblastoma stem cell maintenance.

Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G.

Stem Cells. 2013 May;31(5):857-69. doi: 10.1002/stem.1317.


Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models.

Huang M, Xiong C, Lu W, Zhang R, Zhou M, Huang Q, Weinberg J, Li C.

Mol Imaging Biol. 2014 Feb;16(1):74-84. doi: 10.1007/s11307-013-0674-3.


Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells.

Jin ZH, Sogawa C, Furukawa T, Saito Y, Aung W, Fujibayashi Y, Saga T.

Mol Imaging. 2012 Nov-Dec;11(6):445-50.


Supplemental Content

Support Center